betamethasone phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4667 151-73-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betamethasone phosphate
  • betamethasone sodium phosphate
  • betamethasone disodium phosphate
  • betnesol
  • durabetason
phosphate ester of betamethasone; RN given refers to the di-Na salt (11beta,16beta)-isomer; structure in Negwer,5th ed, 4975
  • Molecular weight: 472.45
  • Formula: C22H30FO8P
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 141.36
  • ALOGS: -2.21
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.06 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
March 3, 1965 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Erythema 55.51 25.09 41 1541 175710 63311730
Macular degeneration 47.13 25.09 19 1563 24357 63463083
Face oedema 43.42 25.09 17 1565 20195 63467245
Throat tightness 33.47 25.09 15 1567 24872 63462568
Angioedema 32.10 25.09 18 1564 47947 63439493
Pharyngeal oedema 27.56 25.09 11 1571 13710 63473730

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 27.46 25.16 11 985 12125 34943810
Intentional self-injury 26.12 25.16 11 985 13760 34942175
Paraesthesia oral 25.78 25.16 8 988 4189 34951746

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Erythema 58.01 21.36 52 2542 223238 79518556
Face oedema 45.79 21.36 21 2573 28115 79713679
Paraesthesia oral 32.43 21.36 15 2579 20456 79721338
Pharyngeal oedema 29.17 21.36 13 2581 16259 79725535
Throat tightness 28.02 21.36 15 2579 27892 79713902
Sopor 25.66 21.36 15 2579 32995 79708799
Angioedema 24.34 21.36 20 2574 76015 79665779
Intentional self-injury 23.29 21.36 14 2580 32405 79709389
Anaphylactic shock 21.94 21.36 14 2580 35982 79705812

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35705 immunosuppressive agents
CHEBI has role CHEBI:65023 anti-asthmatic agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D019141 Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Pruritus associated with dermatoses Indication
Dogs Pruritus associated with dermatoses Indication
Horses Inflammatory joint conditions Indication

🐶 Veterinary products

ProductApplicantIngredients
Betavet Soluspan Suspension Intervet Inc. 2
Betasone Aqueous Suspension Intervet Inc. 2
BetaVet American Regent Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.75 acidic
pKa2 6.8 acidic
pKa3 11.06 acidic
pKa4 13.94 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST Ki 8.43 DRUG MATRIX CHEMBL
Histamine H1 receptor GPCR Ki 5.93 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 5.78 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 5.87 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 5.78 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.25 DRUG MATRIX

External reference:

IDSource
D00972 KEGG_DRUG
4018646 VUID
N0000179655 NUI
4018644 VANDF
4018646 VANDF
CHEBI:3077 CHEBI
CHEMBL1201207 ChEMBL_ID
C028994 MESH_SUPPLEMENTAL_RECORD_UI
DB14669 DRUGBANK_ID
DB00443 DRUGBANK_ID
1514 RXNORM
10006 MMSL
3292 MMSL
33290 MMSL
4270 MMSL
4277 MMSL
d00628 MMSL
002168 NDDF
002172 NDDF
116571008 SNOMEDCT_US
116573006 SNOMEDCT_US
29896003 SNOMEDCT_US
C2698382 UMLSCUI
C0005308 UMLSCUI
CHEMBL1200762 ChEMBL_ID
65478 PUBCHEM_CID
1045 INN_ID
9782 PUBCHEM_CID
D001623 MESH_DESCRIPTOR_UI
7BK02SCL3W UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0720 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0720 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0791 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0791 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0799 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0799 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 51754-5060 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA AUTHORIZED GENERIC 22 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 51754-5060 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA AUTHORIZED GENERIC 22 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 51754-5060 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA AUTHORIZED GENERIC 22 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 51754-5060 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA AUTHORIZED GENERIC 22 sections
ReadySharp Betamethasone HUMAN PRESCRIPTION DRUG LABEL 2 53225-3665 INJECTION, SUSPENSION 3 mg INTRALESIONAL ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 70518-2952 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA authorized generic 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 76420-007 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 76420-007 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betaloan SUIK HUMAN PRESCRIPTION DRUG LABEL 2 76420-240 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR unapproved drug other 21 sections
Betaloan SUIK HUMAN PRESCRIPTION DRUG LABEL 2 76420-240 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR unapproved drug other 21 sections
CELESTONE SOLUSPAN HUMAN PRESCRIPTION DRUG LABEL 2 78206-118 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA 22 sections
CELESTONE SOLUSPAN HUMAN PRESCRIPTION DRUG LABEL 2 78206-118 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA 22 sections
CELESTONE SOLUSPAN HUMAN PRESCRIPTION DRUG LABEL 2 78206-118 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA 22 sections
CELESTONE SOLUSPAN HUMAN PRESCRIPTION DRUG LABEL 2 78206-118 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA 22 sections
Betaloan SUIK HUMAN PRESCRIPTION DRUG LABEL 2 80425-0347 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR unapproved drug other 21 sections